SCHEMBL12156326

SCHEMBL12156326

Cc1ccccc1C(=O)Nc1ccc(-c2cc3c(cc2Cl)CC(F)(F)C3)cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.57
▸ RAB9A P51151 7/20 0.57
▸ ALOX15 P16050 1/20 0.57
▸ HTT P42858 1/20 0.57
▸ TP53 P04637 4/20 0.54
▸ MAPK1 P28482 2/20 0.54
▸ ALDH1A1 P00352 3/20 0.43
▸ SMN1; SMN2 Q16637 5/20 0.43
▸ GAA P10253 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ GLA P06280 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ DHODH Q02127 1/20 0.42
▸ ABL1 P00519 2/20 0.42
▸ LMNA P02545 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ PTBP1 P26599 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ GRM4 Q14833 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12156318 0.91 NPC1 (0.57) NPC1RAB9AALOX15HTTTP53
SCHEMBL12156323 0.89 SMN1; SMN2 (0.58) NPC1RAB9ATP53ALDH1A1SMN1; SMN2
SCHEMBL12155682 0.87 STIM1 (0.52) NPC1RAB9AALOX15HTTTP53
SCHEMBL12155865 0.85 NPC1 (0.53) NPC1RAB9AALOX15HTTTP53
SCHEMBL12156303 0.82 NPC1 (0.58) NPC1RAB9AALOX15HTTTP53
SCHEMBL12155449 0.82 STIM1 (0.57) NPC1RAB9AALOX15HTTTP53
SCHEMBL12156302 0.81 IL2 (0.47) NPC1RAB9AALDH1A1SMN1; SMN2TDP1
SCHEMBL12155578 0.81 NPC1 (0.54) NPC1RAB9AALOX15HTTTP53
SCHEMBL12156321 0.81 ABL1 (0.44) NPC1RAB9AALOX15TP53MAPK1
SCHEMBL15853485 0.81 NPC1 (0.64) NPC1RAB9AALOX15HTTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10703722-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2020-07-07 — — US disclosed
EP-2563776-B1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC (US) 2016-06-08 — — EP disclosed
US-20150322012-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM AVENUE CAPITAL MANAGEMENT II, L.P. 2015-11-12 — — US disclosed
US-9120751-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2015-09-01 — — US disclosed
US-9120751-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2015-09-01 — — US disclosed
US-8980629-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2015-03-17 — — US disclosed
US-8980629-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2015-03-17 — — US disclosed
WO-2011139489-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2011-11-10 — — WO disclosed
US-20110263612-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-10-27 — — US disclosed
US-20110263612-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322012-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 NPC1 262/4885RAB9A 1174/4885ALOX15 1014/4885
US-10703722-B2 Compounds that modulate intracellular calcium ORAI1, SARAF, RYR2 NPC1 262/4885RAB9A 1174/4885ALOX15 1014/4885
US-20110263612-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 NPC1 262/4885RAB9A 1174/4885ALOX15 1014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback